Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy Ratner

Showing results (121-130 of 147) with videos related to

Pageof 15
Sort By:
The Journal of Clinical Investigation|December 23, 2015
Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13Marthe-Sandrine Eiymo Mwa Mpollo, Eric B Brandt, Shiva Kumar Shanmukhappa, et al.
Oncotarget|October 16, 2020
Correction: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicityAdrienne L Watson, Bryant J Keller, Kyle A Williams, et al.
Cancer Research|March 3, 2006
Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissuesShyra J Miller, Fatima Rangwala, Jon Williams, et al.
Frontiers in Immunology|July 24, 2024
Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumorsSiddhi N Paudel, Brian J Hutzen, Katherine E Miller, et al.
The Journal of Clinical Investigation|December 11, 2012
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumorsWalter J Jessen, Shyra J Miller, Edwin Jousma, et al.
Frontiers in Immunology|July 24, 2024
Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumorsSiddhi N Paudel, Brian J Hutzen, Katherine E Miller, et al.
EMBO Molecular Medicine|January 6, 2010
Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival geneShyra J Miller, Walter J Jessen, Tapan Mehta, et al.
Cancer Cell|February 14, 2018
Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath TumorigenesisLai Man Natalie Wu, Yaqi Deng, Jincheng Wang, et al.
Cancer Discovery|March 29, 2013
Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenanceAdrienne L Watson, Eric P Rahrmann, Branden S Moriarity, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform NeurofibromasBrian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Pageof 15

Showing results (121-130 of 147) with videos related to

Sort By:
Pageof 15
The Journal of Clinical Investigation|December 23, 2015
Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13Marthe-Sandrine Eiymo Mwa Mpollo, Eric B Brandt, Shiva Kumar Shanmukhappa, et al.
Oncotarget|October 16, 2020
Correction: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicityAdrienne L Watson, Bryant J Keller, Kyle A Williams, et al.
Cancer Research|March 3, 2006
Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissuesShyra J Miller, Fatima Rangwala, Jon Williams, et al.
Frontiers in Immunology|July 24, 2024
Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumorsSiddhi N Paudel, Brian J Hutzen, Katherine E Miller, et al.
The Journal of Clinical Investigation|December 11, 2012
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumorsWalter J Jessen, Shyra J Miller, Edwin Jousma, et al.
Frontiers in Immunology|July 24, 2024
Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumorsSiddhi N Paudel, Brian J Hutzen, Katherine E Miller, et al.
EMBO Molecular Medicine|January 6, 2010
Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival geneShyra J Miller, Walter J Jessen, Tapan Mehta, et al.
Cancer Cell|February 14, 2018
Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath TumorigenesisLai Man Natalie Wu, Yaqi Deng, Jincheng Wang, et al.
Cancer Discovery|March 29, 2013
Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenanceAdrienne L Watson, Eric P Rahrmann, Branden S Moriarity, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform NeurofibromasBrian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Pageof 15